Drug Profile
BNT 111
Alternative Names: BNT-111; Lipo-MERIT; RB 0003; RB_0003; RBL 001/RBL 002/RBL 003/RBL 004; RBL001.1/RBL002.2/RBL003.1/RBL004.1; RNA-LPX; RNA(LIP); Tetravalent RNA-lipoplex Cancer VaccineLatest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator BioNTech
- Developer BioNTech; Regeneron Pharmaceuticals
- Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Malignant melanoma
Most Recent Events
- 19 Nov 2021 BNT 111 receives Fast Track designation for Malignant melanoma [IV,Injection] (Combination therapy, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in USA
- 09 Nov 2021 Updated immunogenicity data from the phase I LIPO-MERIT trial in Malignant melanoma released by BioNTech
- 15 Sep 2021 BNT 111 receives Orphan Drug status for Malignant melanoma (Late-stage disease) in USA